BROOKS

Brooks Laboratories Financial Results

₹58.90-1.27%
Market cap
₹174 crore
P/E
13.1
P/B
1.41
ROE
22.3%
Dividend yield
1.20%

For the year ended Mar 2019, Brooks Laboratories reported revenue of ₹55 crore and net profit of -₹15 crore, against ₹70 crore and -₹24 crore a year earlier.

Brooks Laboratories annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Brooks Laboratories annual profit and loss (₹ crore)
ItemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue557077916279828583
Expenses6374771058976747877
Operating profit-8-41-14-273876
Operating margin %-15%-6%1%-16%-42%4%10%8%7%
Other income3011-3-20-152010
Interest333321111
Depreciation677772222
Profit before tax-15-14-9-24-38-20-102513
Tax %1%-80%-116%19%19%0%-2%0%0%
Net profit-15-24-19-19-31-20-102513
EPS (₹)-5.94-9.77-7.77-6.49-8.38-7.46-3.388.354.49
Dividend payout %—————————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Brooks Laboratories financial results — frequently asked questions

What is Brooks Laboratories' annual revenue and net profit?

For the financial year ended Mar 2019, Brooks Laboratories' revenue was ₹55 crore and net profit -₹15 crore; net profit rose 37.50% from -₹24 crore in Mar 2020.

How fast has Brooks Laboratories grown over three years?

From Mar 2022 to Mar 2019, Brooks Laboratories' revenue grew at a compound annual rate of -15.5%. Past growth does not indicate future results.

What is the EPS of Brooks Laboratories?

Annual EPS for Mar 2019 was -₹5.94.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Brooks Laboratories With ATS

Track BROOKS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.